- Home
- SPRO vs VFL Comparison
SPRO vs VFL Comparison
Compare SPRO & VFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- VFL
- Stock Information
- Founded
- SPRO 2013
- VFL 1993
- Country
- SPRO United States
- VFL United States
- Employees
- SPRO N/A
- VFL N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- VFL Finance/Investors Services
- Sector
- SPRO Health Care
- VFL Finance
- Exchange
- SPRO Nasdaq
- VFL Nasdaq
- Market Cap
- SPRO 128.9M
- VFL 125.8M
- IPO Year
- SPRO 2017
- VFL N/A
- Fundamental
- Price
- SPRO $2.36
- VFL $10.25
- Analyst Decision
- SPRO Buy
- VFL
- Analyst Count
- SPRO 4
- VFL 0
- Target Price
- SPRO $5.00
- VFL N/A
- AVG Volume (30 Days)
- SPRO 1.2M
- VFL 38.0K
- Earning Date
- SPRO 11-13-2025
- VFL 01-01-0001
- Dividend Yield
- SPRO N/A
- VFL 4.16%
- EPS Growth
- SPRO N/A
- VFL N/A
- EPS
- SPRO N/A
- VFL N/A
- Revenue
- SPRO $48,576,000.00
- VFL N/A
- Revenue This Year
- SPRO N/A
- VFL N/A
- Revenue Next Year
- SPRO N/A
- VFL N/A
- P/E Ratio
- SPRO N/A
- VFL N/A
- Revenue Growth
- SPRO N/A
- VFL N/A
- 52 Week Low
- SPRO $0.51
- VFL $7.93
- 52 Week High
- SPRO $3.22
- VFL $10.77
- Technical
- Relative Strength Index (RSI)
- SPRO 57.47
- VFL 45.96
- Support Level
- SPRO $2.16
- VFL $10.18
- Resistance Level
- SPRO $2.44
- VFL $10.38
- Average True Range (ATR)
- SPRO 0.12
- VFL 0.09
- MACD
- SPRO -0.00
- VFL -0.03
- Stochastic Oscillator
- SPRO 55.24
- VFL 7.47
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.